Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

Research output: Contribution to journalArticle

Authors

  • D Farge
  • J Passweg
  • JM van Laar
  • Z Marjanovic
  • C Besenthal
  • J Finke
  • HH Peter
  • FC Breedveld

Colleges, School and Institutes

Abstract

OBJECTIVE: To analyse the durability of the responses after haematopoietic stem cell transplantation (HSCT) for severe systemic sclerosis (SSc) and determine whether the high transplant related mortality (TRM) improved with experience. This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases. METHODS: Only patients with SSc, treated by HSCT in European phase I-II studies from 1996 up to 2002, with more than 6 months of follow up were included. Transplant regimens were according to the international consensus statements. Repeated evaluations analysed complete, partial, or non-response and the probability of disease progression and survival after HSCT (Kaplan-Meier). RESULTS: Given as median (range). Among 57 patients aged 40 (9.1-68.7) years the skin scores improved at 6 (n = 37 patients), 12 (n = 30), 24 (n = 19), and 36 (n = 10) months after HSCT (p

Details

Original languageEnglish
Pages (from-to)974-81
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume63
Issue number8
Publication statusPublished - 1 Jan 2004